TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00665314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor (AMD3100)
Description: 0.24mg/kg SC for 2 to 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Can be any registered nonpegylated form of G-CSF
Description: 10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
Study: NCT01215266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Day 3-21 2x2 800 mg(milligram) daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 3-21 2x2 800 mg(milligram) daily
Study: NCT04322500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
Study: NCT01931215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with intrathecal morphine
Description: in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP-block with ropivacaine and clonidine
Study: NCT04598191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (Normal saline)
Description: Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done.
Study: NCT03772002

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV screening
Description: HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
Study: NCT02788279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Description: Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Description: Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Study: NCT04674540

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT01529775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Prevail
Description: Osseotite implant with platform switching feature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Certain Tapered
Description: Osseotite implant with non-platform switching feature
Study: NCT02024152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV low dose
Study: NCT01169779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT02024152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IM
Study: NCT01169779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study: NCT02024152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Zyrtec
Study: NCT03449784

Intervention type: OTHER
Intervention: Detection of patients with dyslipidemia
Description: Detection of patients with dyslipidemia

Intervention type: OTHER
Intervention: Detection of patients with dyslipidemia
Description: Detection of patients with dyslipidemia
Study: NCT00618098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octaplex (human prothrombin complex concentrate)
Description: INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
Study: NCT00838864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftrioxone
Description: 500 mg iv q12h for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftrioxone
Description: 500 mg q12h for 7 days
Study: NCT01101308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (Totowa) (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reformulated OXY (Wilson) (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
Study: NCT04837326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling in Facilitated Tucking Position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling When the Infant is Embraced by the Mother

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling Using White Noise
Study: NCT03547115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voruciclib monotherapy
Description: Voruciclib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voruciclib and venetoclax
Description: Voruciclib and Venetoclax will be administered orally
Study: NCT04220593

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
Study: NCT01169779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
Study: NCT02834910

Intervention type: OTHER
Intervention: collection of bacterial sample

Intervention type: OTHER
Intervention: collection of bacterial sample
Study: NCT00348621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual impairment intervention program
Description: enhanced access to eye care services
Study: NCT01736904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wXELIRI regimen
Description: irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Study: NCT04122287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: levofloxacinn-tetracycline-containing quadruple regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: tinidazole-tetracycline-containing quadruple regimens
Study: NCT00603239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
Study: NCT02508155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352 for IV infusion
Description: MEDI7352 for IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IV infusion
Description: IV Placebo infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352 for Subcutaneous Injection
Description: MEDI7352 for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Subcutaneous Injection
Description: Subcutaneous Placebo Injection
Study: NCT00734084

Intervention type: DEVICE
Group type: OTHER
Intervention: Preservation Unicompartmental Knee
Description: Minimally invasive orthopaedic implant for single compartment knee arthritis
Study: NCT03180814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration
Description: A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
Study: NCT04220593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
Study: NCT02111278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Manipulation
Description: The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
Study: NCT04322500

Intervention type: OTHER
Group type: OTHER
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Study: NCT02111278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
Study: NCT04322500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Study: NCT03482427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Heart Score
Description: Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
Study: NCT02073604

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Morphological and functional brain MRI; transcranial magnetic stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Congenital mirror movements
Description: Morphological and functional brain MRI; transcranial magnetic stimulation
Study: NCT01497652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rasagiline/Placebo
Description: Will receive placebo pills each day for the entire 14 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: 0.5 mg for two weeks, then 1 mg for 12 weeks.
Study: NCT03374280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed/cisplatin intercalating gefitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed/cisplatin
Study: NCT01970176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study: NCT04495699

Intervention type: OTHER
Intervention: None - observational
Description: If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
Study: NCT03625388

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Film coated tablet contains dasatinib monohydrate

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Film coated tablet contains dasatinib monohydrate
Study: NCT03345186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse led plus standard of care
Description: structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
Study: NCT01848145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of \>= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE \>= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
Study: NCT05586126

Intervention type: DRUG
Intervention: Sevoflurane
Description: sevoflurane inhalation
Study: NCT04168294

Intervention type: DRUG
Intervention: Propofol
Description: patients in sedation group will be intravenous injected propofol in bolus

Intervention type: DEVICE
Intervention: endoscopy
Description: endoscopy system

Intervention type: DEVICE
Intervention: endoscopy
Description: endoscopy system
Study: NCT04177290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (M1b)
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab (approved)
Description: Intravenous infusion
Study: NCT00595166

Intervention type: DEVICE
Intervention: Vaginal Speculum Sheath
Description: Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
Study: NCT02374853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Topical prophylactic antibiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Vancomycin
Description: Placebo: Sterile water. No Vancomycin.
Study: NCT01333332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Dose Acclerated Fraction Radiotherapy
Description: Standard dose accelerated fraction radiotherapy